Fig. 2From: Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in SwitzerlandEpidemiological impact of two vaccination strategies on HPV16/18/31/33/45/52/58 infection prevalence among males over 100 yearsBack to article page